Balinatunfib + Moxifloxacin + Placebo

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Repolarization

Conditions

Cardiac Repolarization, Healthy Volunteers

Trial Timeline

Dec 4, 2025 → Apr 27, 2026

NCT ID

NCT07272629

About Balinatunfib + Moxifloxacin + Placebo

Balinatunfib + Moxifloxacin + Placebo is a phase 1 stage product being developed by Sanofi for Cardiac Repolarization. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07272629. Target conditions include Cardiac Repolarization, Healthy Volunteers.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07272629	Phase 1	Recruiting	Dec 4, 2025	Apr 27, 2026	Cardiac Repolarization

Competing Products

20 competing products in Cardiac Repolarization

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	77
regadenoson	Astellas Pharma	Pre-clinical	23
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	52
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	23
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	85
Everolimus (RAD001)	Novartis	Phase 3	77
Deferasirox and Deferoxamine	Novartis	Phase 2	52
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	85
TIN816	Novartis	Phase 2	52
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	85
Pirfenidone + Placebo	Roche	Phase 2	52
Daclizumab	Roche	Phase 1/2	41
Ranolazine + Placebo	Gilead Sciences	Phase 3	76
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
Epinephrine	Pfizer	Approved	84
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	51
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	84
BMS-986224	Bristol Myers Squibb	Phase 1	32
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	51
Sotagliflozin + Placebo	Sanofi	Phase 2	51

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved